Algernon

Algernon Pharmaceuticals is a clinical-stage drug development company focused on non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), inflammatory bowel disease (IBD), and idiopathic pulmonary fibrosis (IPF). Algernon Pharmaceuticals' key compounds were identified using a drug repositioning strategy. Drug repositioning is the process of discovering new therapeutic uses for existing drugs. Compared to traditional drug development, repositioning offers many advantages, including reduced investment and risk, shortened research cycles, and extended effective patent life. Algernon protects its lead compounds through proprietary methods of use and new composition patents for its derivative compounds and analogs.